Results 21 to 30 of about 241,431 (287)
Desensitized D2 autoreceptors are resistant to trafficking
Scientific Reports, 2017 Dendritic release of dopamine activates dopamine D2 autoreceptors, which are inhibitory G protein-coupled receptors (GPCRs), to decrease the excitability of dopamine neurons.
Brooks G. Robinson +7 more
doaj +1 more source
Dopamine-D1 and δ-opioid receptors co-exist in rat striatal neurons [PDF]
, 2006 Cocaine’s enhancement of dopaminergic neurotransmission in the mesolimbic pathway plays a critical role in the initial reinforcing properties of this drug. However, other neurotransmitter systems are also integral to the addiction process.
Ambrose-Lanci, L. M. +3 more
core +2 more sources
Mice in ecstasy : advanced animal models in the study of MDMA [PDF]
, 2010 The party drug 3,4-methylenedioxymethamphetamine -better known as MDMA or ecstasy- has numerous effects on the human body, characterized by a rush of energy, euphoria and empathy.
Stove, Christophe +3 more
core +2 more sources
Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. [PDF]
PLoS ONE, 2012 The dopamine D(1), D(2), D(3) receptors, vesicular monoamine transporter type-2 (VMAT2), and dopamine transporter (DAT) densities were measured in 11 aged human brains (aged 77-107.8, mean: 91 years) by quantitative autoradiography.
Jianjun Sun +4 more
doaj +1 more source
Voltage-Dependent Dopamine Potency at D1-Like Dopamine Receptors
Frontiers in Pharmacology, 2020 In recent years, transmembrane voltage has been found to modify agonist potencies at several G protein-coupled receptors (GPCRs). Whereas the voltage sensitivities of the Gαi/o-coupled dopamine D2-like receptors (D2R, D3R, D4R) have previously been ...
Richard Ågren +3 more
doaj +1 more source
A molecular basis for selective antagonist destabilization of dopamine D3 receptor quaternary organization [PDF]
, 2017 The dopamine D3 receptor (D3R) is a molecular target for both first-generation and several recently-developed antipsychotic agents. Following stable expression of this mEGFP-tagged receptor, Spatial Intensity Distribution Analysis indicated that a ...
Caltabiano, Gianluigi +6 more
core +2 more sources
npj Schizophrenia, 2017 Antipsychotic drugs are widely prescribed medications, used for numerous psychiatric illnesses. However, antipsychotic drugs cause serious metabolic side effects that can lead to substantial weight gain and increased risk for type 2 diabetes.
Zachary Freyberg, Michael J. McCarthy
doaj +1 more source
Japanese Journal of Pharmacology, 2000 Initial investigations on dopamine D4 receptors generated much interest in the role of this receptor in schizophrenia and other aspects of human behavior, as well as new opportunities for novel therapeutics. However, attempts to treat patients suffering from schizophrenia with dopamine D4 agents have failed to yield satisfactory results so far.
D M, Helmeste, S W, Tang
openaire +3 more sources
Scientific Reports, 2018 PCC0104005 is a novel drug candidate for treating schizophrenia that displays high affinity for serotonin, dopamine, and noradrenaline receptors, including partial agonism at dopamine D2, D3, D4, serotonin 5-HT1A, and 5-HT2A receptors and antagonism at 5-
Yanan Xu +5 more
doaj +1 more source
Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients
BMC Medical Genetics, 2001 Background Though the dysfunction of central dopaminergic system has been proposed, the etiology or pathogenesis of schizophrenia is still uncertain partly due to limited accessibility to dopamine receptor. The purpose of this study was to define whether
Choi Chul-Hee +3 more
doaj +1 more source